H.C. Wainwright raised the firm’s price target on ALX Oncology to $20 from $17.50 and keeps a Buy rating on the shares following the Q4 report. The analyst sees a “catalyst-rich” 2024 and believes the company could fund operations through 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALXO:
- ALX Oncology price target raised to $21 from $11 at Piper Sandler
- ALX Oncology downgraded to Hold from Buy at Stifel
- ALX Oncology reports Q4 EPS (93c), consensus (84c)
- ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
